AI-generated analysis. Always verify with the original filing.
Autolus Therapeutics plc announced its financial results for the year ended December 31, 2025, reporting AUCATZYL net product revenue of $74.3 million for the full year and providing a 2026 revenue outlook of $120 million to $135 million. The company also provided updates on its clinical pipeline, including progress in pediatric ALL, lupus nephritis, and progressive multiple sclerosis trials.
Event Type
Disclosure
Mandatory
Variant
8-K
, including Exhibit 99.1 attached hereto, is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934,
, including Exhibit 99.2 attached hereto, is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Exchange Act, or otherwise subjec
Financial Statements and Exhibits d) Exhibits Exhibit No. Description of Exhibit 99.1 Press release dated March 2 7, 2 026 99.2 Corporate Presentation dated Mar
| Metric | Value | Basis |
|---|---|---|
| Product revenue, net | $74.32 | |
| Total revenue, net | $75.39 | |
| Loss from operations | $-270.54 | |
| Net loss | $-287.53 | |
| Basic and diluted net loss per ordinary share | $-1.08 |